Jessica Lawrence1, Lara Richer2, Jocelyne Arseneau2, Xing Zeng3, George Chong4, Evan Weber5, William Foulkes1,5,6, Laura Palma1,5. 1. Department of Human Genetics, McGill University, Montreal, QC H3A 0C7, Canada. 2. Department of Pathology, McGill University Health Centre, Montreal, QC H4A 3J1, Canada. 3. Division of Gynecologic Oncology, Departments of Obstetrics and Gynecology, Oncology, and Pathology, McGill University and McGill University Health Centre, Montreal, QC H4A 3J1, Canada. 4. Department of Pathology, Jewish General Hospital, Montreal, QC H3T 1E2, Canada. 5. Division of Medical Genetics, Department of Specialized Medicine, McGill University Health Centre, Montreal, QC H4A 3J1, Canada. 6. Cancer Research Program, Research Institute of the McGill University Health Centre, McGill University, Montreal, QC H4A 3J1, Canada.
Abstract
BACKGROUND: Approximately 2-6% of endometrial cancers (ECs) are due to Lynch Syndrome (LS), a cancer predisposition syndrome caused by germline pathogenic variants (PVs) affecting the DNA mismatch repair (MMR) pathway. Increasingly, universal tissue-based screening of ECs has been proposed as an efficient and cost-effective way to identify families with LS, though few studies have been published on Canadian cohorts. The purpose of this study was to evaluate the feasibility and overall performance of a universal immunohistochemistry (IHC) screening program for women with EC within a single Canadian university hospital centre. METHODS AND RESULTS: From 1 October 2015 to 31 December 2017, all newly diagnosed ECs (n = 261) at our centre were screened for MMR protein deficiency by IHC. MMR deficiency was noted in 69 tumours (26.4%), among which 53 had somatic MLH1 promoter hypermethylation and were considered "screen-negative". The remaining MMR-deficient cases (n = 16) were considered "screen-positive" and were referred for genetic counselling and testing. Germline PVs were identified in 12/16 (75%). One additional PV was identified in a screen-negative individual who was independently referred to the Genetics service. This corresponds to an overall LS frequency of 5.0% among unselected women with EC, and 6.4% among women diagnosed under age 70 years. Our algorithm detected MMR gene pathogenic variants in 4.6% and 6.2% of unselected individuals and individuals under age 70 years, respectively. Four germline PVs (30.8%) were identified in individuals who did not meet any traditional LS screening criteria. CONCLUSIONS: Universal IHC screening for women with EC is an effective and feasible method of identifying individuals with LS in a Canadian context.
BACKGROUND: Approximately 2-6% of endometrial cancers (ECs) are due to Lynch Syndrome (LS), a cancer predisposition syndrome caused by germline pathogenic variants (PVs) affecting the DNA mismatch repair (MMR) pathway. Increasingly, universal tissue-based screening of ECs has been proposed as an efficient and cost-effective way to identify families with LS, though few studies have been published on Canadian cohorts. The purpose of this study was to evaluate the feasibility and overall performance of a universal immunohistochemistry (IHC) screening program for women with EC within a single Canadian university hospital centre. METHODS AND RESULTS: From 1 October 2015 to 31 December 2017, all newly diagnosed ECs (n = 261) at our centre were screened for MMR protein deficiency by IHC. MMR deficiency was noted in 69 tumours (26.4%), among which 53 had somatic MLH1 promoter hypermethylation and were considered "screen-negative". The remaining MMR-deficient cases (n = 16) were considered "screen-positive" and were referred for genetic counselling and testing. Germline PVs were identified in 12/16 (75%). One additional PV was identified in a screen-negative individual who was independently referred to the Genetics service. This corresponds to an overall LS frequency of 5.0% among unselected women with EC, and 6.4% among women diagnosed under age 70 years. Our algorithm detected MMR gene pathogenic variants in 4.6% and 6.2% of unselected individuals and individuals under age 70 years, respectively. Four germline PVs (30.8%) were identified in individuals who did not meet any traditional LS screening criteria. CONCLUSIONS: Universal IHC screening for women with EC is an effective and feasible method of identifying individuals with LS in a Canadian context.
Authors: Roland P Kuiper; Lisenka E L M Vissers; Ramprasath Venkatachalam; Danielle Bodmer; Eveline Hoenselaar; Monique Goossens; Aline Haufe; Eveline Kamping; Renée C Niessen; Frans B L Hogervorst; Johan J P Gille; Bert Redeker; Carli M J Tops; Marielle E van Gijn; Ans M W van den Ouweland; Nils Rahner; Verena Steinke; Philip Kahl; Elke Holinski-Feder; Monika Morak; Matthias Kloor; Susanne Stemmler; Beate Betz; Pierre Hutter; David J Bunyan; Sapna Syngal; Julie O Culver; Tracy Graham; Tsun L Chan; Iris D Nagtegaal; J Han J M van Krieken; Hans K Schackert; Nicoline Hoogerbrugge; Ad Geurts van Kessel; Marjolijn J L Ligtenberg Journal: Hum Mutat Date: 2011-03-01 Impact factor: 4.878
Authors: Sanne W ten Broeke; Richard M Brohet; Carli M Tops; Heleen M van der Klift; Mary E Velthuizen; Inge Bernstein; Gabriel Capellá Munar; Encarna Gomez Garcia; Nicoline Hoogerbrugge; Tom G W Letteboer; Fred H Menko; Annika Lindblom; Arjen R Mensenkamp; Pal Moller; Theo A van Os; Nils Rahner; Bert J W Redeker; Rolf H Sijmons; Liesbeth Spruijt; Manon Suerink; Yvonne J Vos; Anja Wagner; Frederik J Hes; Hans F Vasen; Maartje Nielsen; Juul T Wijnen Journal: J Clin Oncol Date: 2014-12-15 Impact factor: 44.544
Authors: Amanda S Bruegl; Bojana Djordjevic; Brittany Batte; Molly Daniels; Bryan Fellman; Diana Urbauer; Rajyalakshmi Luthra; Charlotte Sun; Karen H Lu; Russell R Broaddus Journal: Cancer Prev Res (Phila) Date: 2014-04-25
Authors: Brittany A L Batte; Amanda S Bruegl; Molly S Daniels; Kari L Ring; Katherine M Dempsey; Bojana Djordjevic; Rajyalakshmi Luthra; Bryan M Fellman; Karen H Lu; Russell R Broaddus Journal: Gynecol Oncol Date: 2014-06-14 Impact factor: 5.482
Authors: Pål Møller; Toni Seppälä; Inge Bernstein; Elke Holinski-Feder; Paola Sala; D Gareth Evans; Annika Lindblom; Finlay Macrae; Ignacio Blanco; Rolf Sijmons; Jacqueline Jeffries; Hans Vasen; John Burn; Sigve Nakken; Eivind Hovig; Einar Andreas Rødland; Kukatharmini Tharmaratnam; Wouter H de Vos Tot Nederveen Cappel; James Hill; Juul Wijnen; Kate Green; Fiona Lalloo; Lone Sunde; Miriam Mints; Lucio Bertario; Marta Pineda; Matilde Navarro; Monika Morak; Laura Renkonen-Sinisalo; Ian M Frayling; John-Paul Plazzer; Kirsi Pylvanainen; Julian R Sampson; Gabriel Capella; Jukka-Pekka Mecklin; Gabriela Möslein Journal: Gut Date: 2015-12-09 Impact factor: 23.059
Authors: Elizabeth Dicks; Daryl Pullman; Ken Kao; Andrée MacMillan; Gabrielle S Logan; Charlene Simmonds; Holly Etchegary Journal: Cancer Med Date: 2019-05-17 Impact factor: 4.452
Authors: Petra W C Lee; Angela C Bedard; Setareh Samimi; Vivienne K Beard; Quan Hong; James E J Bedard; Blake Gilks; David F Schaeffer; Robert Wolber; Janice S Kwon; Howard J Lim; Sophie Sun; Kasmintan A Schrader Journal: Cancer Med Date: 2020-07-23 Impact factor: 4.452
Authors: Piotr Olcha; Anna Winiarska-Mieczan; Małgorzata Kwiecień; Łukasz Nowakowski; Andrzej Miturski; Andrzej Semczuk; Bożena Kiczorowska; Krzysztof Gałczyński Journal: Int J Mol Sci Date: 2022-06-16 Impact factor: 6.208